FSTX 0.00 F-star Therapeutics, Inc.
| Range: | 2.07-7.12 | Vol Avg: | 747281 | Last Div: | 0 | Changes: | 0 |
| Beta: | -0.35 | Cap: | 0.16B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri May 06 2016 | Empoloyees: | 84 | ||
| CUSIP: | 30315R107 | CIK: | 0001566373 | ISIN: | US30315R1077 | Country: | GB |
| CEO: | Dr. Eliot Richard Forster M.B.A., Ph.D. | Website: | https://www.f-star.com | ||||
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow